Abstract
Luteinizing hormone-releasing hormone (GnRH) antagonists competitively block pituitary GnRH receptors, thus leading to an immediate decrease of the circulating levels of follicle stimulating hormone (FSH) and luteinizing hormone (LH) and consequently of sex steroids. They are clinically used when pharmacologically induced hormone suppression is desired, e.g. in sex steroid dependent benign and malignant diseases and for prevention of premature LH surges in assisted reproduction. The article reviews the clinical experience with the well established GnRH antagonists cetrorelix, ganirelix and the approved, but recently withdrawn abarelix. Clinical studies with the new depot formulations of cetrorelix, teverelix, degarelix and D-63153 are summarized.
Keywords: GnRH antagonists, cancer, sex-steroid dependent disease, in vitro fertilization, cetrorelix, review
Letters in Drug Design & Discovery
Title: New Peptidic GnRH Antagonists Offer a Broad Range of Therapeutic Applications
Volume: 2 Issue: 7
Author(s): Engel J.B, Diedrich K and Honig A
Affiliation:
Keywords: GnRH antagonists, cancer, sex-steroid dependent disease, in vitro fertilization, cetrorelix, review
Abstract: Luteinizing hormone-releasing hormone (GnRH) antagonists competitively block pituitary GnRH receptors, thus leading to an immediate decrease of the circulating levels of follicle stimulating hormone (FSH) and luteinizing hormone (LH) and consequently of sex steroids. They are clinically used when pharmacologically induced hormone suppression is desired, e.g. in sex steroid dependent benign and malignant diseases and for prevention of premature LH surges in assisted reproduction. The article reviews the clinical experience with the well established GnRH antagonists cetrorelix, ganirelix and the approved, but recently withdrawn abarelix. Clinical studies with the new depot formulations of cetrorelix, teverelix, degarelix and D-63153 are summarized.
Export Options
About this article
Cite this article as:
Engel J.B , Diedrich K and Honig A , New Peptidic GnRH Antagonists Offer a Broad Range of Therapeutic Applications, Letters in Drug Design & Discovery 2005; 2 (7) . https://dx.doi.org/10.2174/157018005774479195
DOI https://dx.doi.org/10.2174/157018005774479195 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Methods for Individualization of Psychotropic Drug Treatment
Current Pharmacogenomics Inotropic and Vasoactive Drugs in Pediatric ICU
Current Drug Targets Rationale of Statin Therapy in Septic Patients
Current Vascular Pharmacology Drug Interactions of Tipranavir, a New HIV Protease Inhibitor
Drug Metabolism Letters Immunotherapy of Melanoma
Current Molecular Pharmacology Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Ethosomes as Novel Vesicular Carrier: An Overview of the Principle, Preparation and its Applications
Current Drug Delivery Mechanism-Based Treatment in Chronic Neuropathic Pain: The Role of Antidepressants
Current Pharmaceutical Design Current Management and Treatment of Cerebral Vasospasm Complicating SAH
CNS & Neurological Disorders - Drug Targets Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Current Drug Therapy Does Daily Dialysis Improve Hypertension in Chronic Haemodialysis Patients?
Current Hypertension Reviews Carotid Artery Stenting for the Prevention of Thromboembolic Stroke
Vascular Disease Prevention (Discontinued) Organosulphur Compounds Induce Apoptosis and Cell Cycle Arrest in Cervical Cancer Cells via Downregulation of HPV E6 and E7 Oncogenes
Anti-Cancer Agents in Medicinal Chemistry Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders A Comprehensive Study of Pharmacological Behaviors, Nano-Formulations, and Applications of Rosemary
The Natural Products Journal Possible Therapies of Septic Shock: Based on Animal Studies and Clinical Trials
Current Pharmaceutical Design The Synthetic Cannabinoids Phenomenon
Current Pharmaceutical Design Carbon Monoxide and the Brain: Time to Rethink the Dogma
Current Pharmaceutical Design The Diagnosis of Drug-Induced Liver Disease
Current Clinical Pharmacology Recent Advances in the Treatment of Neurogenic Erectile Dysfunction
Recent Patents on CNS Drug Discovery (Discontinued)